The current research on AMPs has reached a consensus that AMPs are more suitable for local treatment than systemic drugs, which has been verified in the clinical transformation of AMPs, and most of the AMPs in clinical research are applied to diabetic hand-foot-mouth disease and skin wound infection [18], and a large number of studies have shown that the AMPs (LL-37, cecropin A, NZ2114, and N6) can effectively eradicate biofilm [19,20,21,22], which indicates a great application prospect of AMPs in biofilm inhibition and wound healing of skin infection [23,24]. The gene discussed is ADSL; the disease is skin infection.